Angelo P Tanna

Angelo P Tanna, MD is Vice Chairman and Professor of Ophthalmology and Director of the Glaucoma Service at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. He has served on the faculty since 1999, establishing himself as a leading expert in glaucoma diagnosis and treatment. Dr. Tanna holds multiple leadership positions including Chair of the American Academy of Ophthalmology's Basic and Clinical Science Course Glaucoma Committee.

Dr. Tanna's research interests span several critical areas in ophthalmology, with a primary focus on glaucoma. His work encompasses the efficacy and safety of glaucoma medications, detection of glaucoma progression, and assessment of visual function in glaucoma patients. He has made significant contributions to understanding the impact of cataract on visual field testing in glaucoma and has developed new methods to detect visual field deterioration. His research also includes improving outcomes of incisional glaucoma surgery and innovative approaches using hydrogel polymers to prevent fibrosis after trabeculectomy.

Analysis of Dr. Tanna's recent publications reveals a strong emphasis on applying advanced technologies to glaucoma management, including deep learning algorithms for visual field progression detection using OCT imaging. His work increasingly explores social determinants of health in glaucoma care, healthcare access disparities, and the relationship between systemic conditions and ocular health. The COAST clinical trial he leads represents a significant contribution to optimizing laser trabeculoplasty protocols for glaucoma treatment.

• Secretariat Award, American Academy of Ophthalmology (2019)
• Senior Achievement Award, American Academy of Ophthalmology (2017)
• Continuously listed in Best Doctors in America since 2005
• Outstanding Teacher Award, Northwestern University Feinberg School of Medicine (2020)
• Multiple visiting professorships at leading institutions including Columbia University (2023)

Dr. Tanna has served in various leadership roles in the American Glaucoma Society, including twice as a board member and as Chair (2010-2011). He currently chairs the American Academy of Ophthalmology's Basic and Clinical Science Course Glaucoma Committee and serves on editorial boards of prestigious journals including Ophthalmology and Survey of Ophthalmology. His COAST clinical trial investigates optimal selective laser trabeculoplasty protocols for treating glaucoma, potentially reshaping treatment guidelines. Dr. Tanna also leads research collaborations with biomedical engineers and geneticists, resulting in discoveries such as the association of ANGPT1 region SNPs with primary open-angle glaucoma.